Psychiatry Advisor

Psychiatry Advisor

Our goal is to support mental health professionals by providing them with in-depth and practical information on clinical practices and medications. This information is designed to align with both current trends and new developments in care, enabling clinicians to enhance the outcomes for their patients.

National
English
Online/Digital

Outlet metrics

Domain Authority
59
Ranking

Global

#659981

United States

#266578

Health/Mental Health

#775

Traffic sources
Monthly visitors

Articles

  • 2 days ago | psychiatryadvisor.com | Jaymin Kang

    Topline data were announced from a phase 3 trial evaluating CTx-1301 for the treatment of pediatric patients aged 6 to 17 years with attention deficit/hyperactivity disorder (ADHD). CTx-1301 is a novel proprietary formulation of , a stimulant that increases norepinephrine and dopamine activity in the brain.

  • 4 days ago | psychiatryadvisor.com | Ron Goldberg

    Throughout adulthood, intolerance of uncertainty (IU) changes significantly, and there may be a direct correlation between IU and anxiety, according to a scoping review and meta-analysis study published in the Journal of Anxiety Disorders.

  • 1 week ago | psychiatryadvisor.com | Lisa M Kuhns

    Ketamine and esketamine treatments significantly reduce suicide-related emergency department (ED) visits in patients with treatment-resistant depression (TRD), according to study results presented at the American Psychiatric Association Annual Meeting, held virtually from May 17 to 21, 2025 in Los Angeles, California.

  • 1 week ago | psychiatryadvisor.com | Ron Goldberg

    Black individuals in the United States with diabetes and mild cognitive impairment (MCI) have worse glycemic control and worse depression, according to study results presented at the American Psychiatric Association Annual Meeting, held virtually from May 17 to 21, 2025 in Los Angeles, California. Researchers assessed Black individuals with normal cognition (NC) and MCI for associations between cognitive function, diabetes distress, depression, and diabetes control.

  • 2 weeks ago | psychiatryadvisor.com | Jessica Nye

    Neurosteroids may have a therapeutic application in the management of mood and neurological disorders, according to results of a review presented at the American Psychiatric Association Annual Meeting, held virtually from May 17 to 21, 2025 in Los Angeles, California. Neurosteroids, such as brexanolone, ganaxalone, sepranolone, and zuranolone may have clinical application for managing mood and neurological disorders.

Contact details

Address

123 Example Street

City, Country 12345

Email Patterns

Socials

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Traffic locations